ACETYLSALICYLIC ACID FOR THROMBOEMBOLISM PROPHYLAXIS. DOES IT REALLY WORK OR IT’S A GRIMACE OF THE EVIDENCE-BASED MEDICINE?

Cover Page


Cite item

Abstract

Acetylsalicylic acid administration for pharmaceutical prophylaxis of thromboembolic complications is a highly controversial and debatable issue. Debates continue, and, in particularly, opposite views of ACCP recommendations (8th and 9th revisions), Russian clinical recommendations and AAOS guideline were discussed during the Vreden’s Readings conference in 2017 and motivated the authors to compile the present analytical review. The authors attempted to explain initial ban for use and later on sudden advisable use of acetylsalicylic acid for thromboembolism prophylaxis. There can be no unique answer to such a problem due to ambiguity of current state of evidence-based medicine and current system for defining the clinical guidelines.

About the authors

A. P. Sereda

Federal Medical Biological Agency

Author for correspondence.
Email: drsereda@gmail.com

Dr. Sci. (Med), Deputy Head

30, Volokolamskoye shosse, 23182, Moscow

Russian Federation

References

  1. Hill J., Treasure T.; Guideline Development Group. Reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in patients admitted to hospital: summary of the NICE guideline. Heart. 2010;96(11):879-882. doi: 10.1136/hrt.2010.198275.
  2. Scottish Intercollegiate Network Guidelines (SIGN) Guideline no. 62: Prophylaxis of venous thromboembolism. Available at: http://www.sign.ac.uk/ guidelines/fulltext/62/index.html. Accessed on 05/10/10
  3. Nicolaides A.N., Breddin H.K., Fareed J., Goldhaber S., Haas S., Hull R. et al. Prevention of venous thromboembolism. International Consensus Statement. Guidelines compiled in accordance with the scientific evidence. Int Angiol. 2001;20(1):1-37.
  4. National Health and Medical Research Council. Clinical practice guideline for the prevention of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in patients admitted to Australian hospitals. Melbourne: National Health and Medical Research Council; 2009. https://www.nhmrc.gov.au/_files_nhmrc/ file/publications/cp115_guideline_prevention_venous_ thromboembolism_160722_rescinded.pdf
  5. Falck-Ytter Y., Francis C.W., Johanson N.A., Curley C., Dahl O.E., Schulman S., Ortel T.L., Pauker S.G., Colwell C.W. Jr. Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians EvidenceBased Clinical Practice Guidelines Chest. 2012;141 (2 Suppl):e278-e325. doi: 10.1378/chest.11-2404.
  6. Geerts W.H., Pineo G.F., Heit J.A., Bergqvist D., Lassen M.R., Colwell C.W., Ray J.G. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004; 126 (3 Suppl):338S-400S. doi: 10.1378/chest.126.3_suppl.338S.
  7. Geerts WH., Bergqvist D, Pineo G.F., Heit J.A., Samama C.M., Lassen M.R., Colwell C.W. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 suppl):381S-453S. doi: 10.1378/chest.08-0656.
  8. American Academy of Orthopaedic Surgeons clinical guideline on prevention of symptomatic pulmonary embolism in patients undergoing total hip or knee arthroplasty. Available at: http://www.aaos.org/ research/guidelines/VTE/VTE_full_guideline.pdf.
  9. Российские клинические рекомендации «Профилактика венозных тромбоэмболических осложнений в травматологии и ортопедии». Травматология и ортопедия России. 2012; 1(приложение) :2-24. [Russian clinical guidelines «Prevention of venous thromboembolic complications in traumatology and orthopedics»]. Travmatologiya i ortopediya Rossii [Traumatology and orthopedics of russia]. 2012;1(suppl):1-24. (in Russian).
  10. Arcelus J.I., Villar J.M., Muñoz N. Should we follow the 9th ACCP guidelines for VTE prevention in surgical patients? Thromb Res. 2012;130(Suppl 1):S4-6. doi: 10.1016/j.thromres.2012.08.260.
  11. Guyatt G.H., Oxman A.D., Vist G.E., Kunz R., Falck-Ytter Y., Alonso-Coello P., Schünemann H.J.; GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924-926. doi: 10.1136/bmj.39489.470347.AD.
  12. Guyatt G., Akl E.A., Hirsh J., Kearon C., Crowther M., Gutterman D., Lewis S.Z., Nathanson I., Jaeschke R., Schünemann H. The vexing problem of guidelines and conflict of interest: a potential solution. Ann Intern Med. 2010;152(11):738-741. doi: 10.7326/0003-4819-152-11-201006010-00254.
  13. Haas S.B., Barrack R.L., Westrich G., Lachiewicz P.F. Venous thromboembolic disease after total hip and knee arthroplasty. J Bone Joint Surg Am. 2008;90(12):2764-2780.
  14. Johanson N.A., Lachiewicz P.F., Lieberman J.R., Lotke P.A., Parvizi J., Pellegrini V., Stringer T.A,. Tornetta P. 3rd, Haralson R.H. 3rd, Watters W.C. 3rd. American academy of orthopaedic surgeons clinical practice guideline on. Prevention of symptomatic pulmonary embolism in patients undergoing total hip or knee arthroplasty. J Bone Joint Surg Am. 2009;91(7):1756- 7175. doi: 10.2106/JBJS.I.00511.
  15. Guyatt G.H., Akl E.A., Crowther M., Schünemann H.J., Gutterman D.D., Lewis S.Z. Introduction to the ninth edition: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):48S-52S. doi: 10.1378/chest.11-2286.
  16. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. Lancet. 2000;355(9212): 1295-1302.
  17. Alfaro M.J., Páramo J.A., Rocha E. Prophylaxis of thromboembolic disease and platelet-related changes following total hip replacement: a comparative study of aspirin and heparin-dihydroergotamine. Thromb Haemost. 1986;56(1):53-56 .
  18. Dechavanne M., Ville D., Viala J.J. , Kher A., Faivre J., Pousset M.B., Dejour H. Controlled trial of platelet anti-aggregating agents and subcutaneous heparin in prevention of postoperative deep vein thrombosis in high risk patients. Haemostasis. 1975;4(2):94-100.
  19. Harris W.H., Salzman E.W., Athanasoulis C.A., Waltman A.C., DeSanctis R.W. Aspirin prophylaxis of venous throm-boembolism after total hip replacement. N Engl J Med. 1977;297(23):1246-1249.
  20. McBride J.A., Turpie A.G., Kraus V., Hilz C. Proceedings: failure of aspirin and dipyridamole to influence the incidence of leg scan detected venous thrombosis after elective hip surgery. Thromb Diath Haemorrh. 1975;34(2):564 .
  21. Sautter R.D., Koch E.L., Myers W.O., Ray J.R. 3rd, Mazza J.J., Larson D.E. et al. Aspirin-sulfinpyrazone in prophylaxis of deep venous thrombosis in total hip replacement. JAMA. 1983;250(19):2649-2654 .
  22. McKenna R., Galante J., Bachmann F., Wallace D.L., Kaushal P.S., Meredith P. Prevention of venous thromboembolism after total knee replacement by highdose aspirin or intermittent calf and thigh compression. BMJ. 1980;280(6213):514-517 .
  23. Encke A., Stock C., Dumke H.O. Double-blind study for the prevention of postoperative thrombosis. Chirurg. 1976; 4 (12):670-673. (in German]).
  24. Morris G.K., Mitchell J.R. Preventing venous thromboembo-lism in elderly patients with hip fractures: studies of low-dose heparin, dipyridamole, aspirin, and flurbiprofen . BMJ. 1977;1(6060):535-537.
  25. Powers P.J., Gent M., Jay R.M., Julian D.H., Turpie A.G., Levine M., Hirsh J. A randomized trial of less intense postoperative warfarin or aspirin therapy in the prevention of venous thromboembolism after surgery for fractured hip. Arch Intern Med. 1989; 149(4):771-774.
  26. Snook G.A., Chrisman O.D., Wilson T.C. Thromboembolism after surgical treatment of hip fractures. Clin Orthop Relat Res. 1981;(155):21-24 .
  27. Wood E.H., Prentice C.R., McGrouther D.A., Sinclair J., McNicol G.P. Trial of aspirin and RA 233 in prevention of post-operative deep vein thrombosis. Thromb Diath Haemorrh. 1973;30(1):18-24.
  28. Zekert F., Kohn P., Vormittag E., Poigenfürst J., Thien M. [Prevention of thromboembolism using acetylsalicylic acid in the surgery of hip-joint proximal fractures]. Monatsschr Unfallheilkd Versicher Versorg Verkehrsmed.1974;77(3):97-110. (in German).
  29. Westrich G.H., Bottner F., Windsor R.E., Laskin R.S., Haas S.B., Sculco T.P. VenaFlow plus Lovenox vs VenaFlow plus aspirin for thromboembolic disease prophylaxis in total knee arthroplasty. J Arthroplasty. 2006;21(6 suppl 2):139-143.
  30. Graor R.A.S.J., Lotke P.A., Davidson B.L. RD heparin (ardeparin sodium) vs. aspirin to prevent deep venous thrombosis after hip or knee replacement surgery [abstract] . Chest. 1992 ; 102 (suppl): 118S.
  31. National Institute for Health and Clinical Excellence. Reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in inpatients under-going surgery. NICE clinical guideline No. 46:1-160. Available at: http://www.nice.org.uk/ CG046. Accessed March 31, 2008.
  32. Antiplatelet Trialists’ Collaborative overview of randomised trials of antiplatelet therapy--III: Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. Antiplatelet Trialists’ Collaboration. BMJ. 1994;308(6923):235-246.
  33. Cohen A.T., Skinner J.A., Kakkar V.V. Antiplatelet treatment for thromboprophylaxis: a step forward or backwards? BMJ. 1994;309:1213-1215.
  34. Lieberman JR., Heckmann N. Venous thromboembolism prophylaxis in total hip arthroplasty and total knee arthroplasty patients: from guidelines to practice. J Am Acad Orthop Surg. 2017;25(12):789-798. doi: 10.5435/JAAOS-D-15-00760.
  35. Westrich G.H., Sculco T.P. Prophylaxis against deep venous thrombosis after total knee arthroplasty: pneumatic planter compression and aspirin compared with aspirin alone. J Bone Joint Surg Am. 1996;78(6):826-834.
  36. Gent M., Hirsh .J, Ginsberg J.S., Powers P.J., Levine M.N., Geerts W.H., Jay R.M., Leclerc J., Neemeh J.A., Turpie A.G. Low-molecular-weight heparinoid orgaran is more effective than aspirin in the prevention of venous thromboembolism after surgery for hip fracture. Circulation. 1996;93(1):80-84.
  37. Bergqvis D., Arcelus J.I., Felicissimo P.; ETHOS investigators. Evaluation of the duration of thromboembolic prophylaxis after high-risk orthopedic surgery: The ETHOS observational study. Thromb Haemost. 2012;107(2):270-279. doi: 10.1160/TH11-07-0463.
  38. Cohen A.T., Tapson V.F., Bergmann J.F., Goldhaber S.Z., Kakkar A.J., Deslandes B., Huang W., Zayaruzny M., Emery L., Anderson F.A. Jr; ENDORSE Investigators. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet. 2008;371(9610): 387-394. doi: 10.1016/S0140-6736(08)60202-0.
  39. Bozic K.J., Vail T.P., Pekow P.S., Maselli J.H., Lindenauer P.K., Auerbach A.D. Does aspirin have a role in venous thromboembolism prophylaxis in total knee arthroplasty patients? J Arthroplasty. 2010;25(7):1053-1060. doi: 10.1016/j.arth.2009.06.021.
  40. Khatod M., Inacio M.C.S., Bini S.A., Paxton E.W. Pulmonary embolism prophylaxis in more than 30, 000 total knee arthroplasty patients: is there a best choice? J Arthroplasty. 2012;27(2):167-172. doi: 10.1016/j.arth.2011.04.006.
  41. Lotke P.A., Lonner J.H. The benefit of aspirin chemoprophylaxis for thromboembolism after total knee arthroplasty. Clin Orthop Relat Res. 2006;452:175-180. doi: 10.1097/01.blo.0000238822.78895.95
  42. A prospective comparison of warfarin to aspirin for thromboprophylaxis in total hip and total knee arthroplasty. J Arthroplasty. 2012;27(1):1-9.e2. doi: 10.1016/j.arth.2011.03.032.
  43. Vulcano E., Gesell M., Esposito A., Ma Y., Memtsoudis S.G., Gonzalez Della Valle A. Aspirin for elective hip and knee arthroplasty: a multimodal thromboprophylaxis protocol. Int Orthop. 2012;36(10):1995-2002. doi: 10.1007/s00264-012-1588-4.
  44. Anderson D.R., Dunbar M.J., Bohm E.R., Belzile E., Kahn S.R., Zukor D., Fisher W., Gofton W., Gross P., Pelet S., Crowther M., MacDonald S., Kim P., Pleasance S., Davis N., Andreou P., Wells P., Kovacs M., Rodger M.A., Ramsay T., Carrier M., Vendittoli P.A. Aspirin versus low-molecularweight heparin for extended venous thromboembolism prophylaxis after total hip arthroplasty: a randomized trial. Ann Intern Med. 2013;158(11):800-806. doi: 10.7326/0003-4819-158-11-201306040-00004.
  45. Aquilina A.L., Brunton L.R., Whitehouse M.R., Sullivan N., Blom A.W. Direct thrombin inhibitor (DTI) vs. aspirin in primary total hip and knee replacement using wound ooze as the primary outcome measure. A prospective cohort study. Hip Int. 2012;22(1):22-27. doi: 10.5301/HIP.2012.9058.
  46. Intermountain Joint Replacement Center Writing Committee. A prospective comparison of warfarin to aspirin for thromboprophylaxis in total hip and total knee arthroplasty. J Arthroplasty. 2012 Jan;27(1):1-9.e2. Epub 2011 May 31. doi: 10.1016/j.arth.2011.03.032.

Copyright (c)



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies